Caricamento...
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
OBJECTIVE: To examine whether lowering plasma glucose concentration with the sodium-glucose transporter-2 inhibitor empagliflozin improves β-cell function in patients with type 2 diabetes mellitus (T2DM). METHODS: Patients with T2DM (N = 15) received empagliflozin (25 mg/d) for 2 weeks. β-Cell funct...
Salvato in:
| Pubblicato in: | J Clin Endocrinol Metab |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Endocrine Society
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7328850/ https://ncbi.nlm.nih.gov/pubmed/29342295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2017-01838 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|